Maybe they get healthier with some weight loss, and there may be some secondary gains, George says
Document consent with signed forms in the medical record
Tirzepatide (dual GIP/GLP-1 agonist, not yet formally approved for obesity in the EU): in the SURMOUNT-1 study, resulted in an average weight loss of up to 22.5% at 72 weeks with the 15 mg weekly dose, approaching the effectiveness observed with some bariatric procedures
If you are managing a prescription for Semaglutide or a related GLP-1 medication such as Rybelsus, keeping track of digestive symptoms alongside your dosing schedule can make these conversations with your provider more productive
Some states may cover Ozempic if its on their preferred drug list, with certain clinical criteria such as: A diagnosis of type 2 diabetes Clinical evidence of step therapy with another lower-cost type 2 medication such as metformin Documented A1C levels (lab value indicating blood sugar levels) If Ozempic isnt on your Medicaid plans formulary and is considered a nonpreferred drug, you may still be able to obtain Medicaid coverage if you meet additional criteria
